Evidence map›Paper›PMID 32678290›Full record

ArticleLeukemia2020

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.

Vinayak Venkataraman, Keagan S Casey, Maristela Onozato, Paola Dal Cin, Valentina Nardi, Philip C Amrein, Meghan K Bergeron, Andrew M Brunner, Amir T Fathi, Julia E Foster and 7 more

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vinayak VenkataramanDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Keagan S CaseyDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Maristela OnozatoDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Paola Dal CinDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Valentina NardiDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Philip C AmreinDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Meghan K BergeronDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Andrew M BrunnerDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Amir T FathiDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Julia E FosterDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Jenna MoranDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Timothy A GraubertDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hanno HockDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5201-9403
Chrisa HunnewellDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Matthew J FrigaultDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Steven McAfeeDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Gabriela S HobbsDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA. ghobbs@partners.org.ORCID http://orcid.org/0000-0002-0199-9333

Funding

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
NCI NIH HHS K12 CA087723
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CD19Immunotherapy, AdoptiveBlast CrisisDisease ManagementDisease SusceptibilityHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleOncogene Proteins, FusionReceptors, Chimeric AntigenTreatment OutcomeYoung AdultAntigens, CD19inv(16) fusion protein, humanOncogene Proteins, FusionReceptors, Chimeric Antigen

Identifiers

PMID32678290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.